NAION

2024 - 7 - 4

Skæbnen for dit syn: Ozempic og Wegovy forbundet med øjenlidelse

GLP-1-medicin - højere risiko for udvikling af øjensygdom - NAION - Novo Nordisk - optisk neuropati - Ozempic - semaglutid - Wegovy

Ny forskning afslører en skræmmende sammenhæng mellem vægttabsmedicinen Ozempic og Wegovy og en alvorlig øjenlidelse, der kan føre til blindhed. Læs mere her!

Ny forskning har sat fokus på en potentiel forbindelse mellem Novo Nordisks GLP-1-medicin Ozempic og Wegovy og en alvorlig øjensygdom kaldet NAION. En ledende undersøgelse fra Massachusetts Eye and Ear viser, at personer ordineret semaglutid, solgt som Ozempic og Wegovy, har en øget risiko for at udvikle denne øjenlidelse. NAION kan medføre irreversible synstab og er en sjælden, men alvorlig komplikation. Undersøgelser tyder på, at personer med diabetes, der tager disse medikamenter, har fire gange større risiko for at blive diagnosticeret med sygdommen i synsnerven. Resultater offentliggjort i JAMA Ophthalmology indikerer, at brugen af Wegovy (semaglutid) potentielt kan øge forekomsten af NAION hos diabetespatienter. Det er afgørende at være opmærksom på risiciene ved disse populære vægttabsmediciner for at undgå alvorlige synproblemer.

Post cover
Image courtesy of "STAT"

Study links Ozempic to higher risk of eye condition that can cause ... (STAT)

A new study reports for the first time a potential link between Novo Nordisk's GLP-1 drugs Ozempic and Wegovy and an eye condition, NAION.

Popular Prescription Weight Loss Drugs Linked to Uncommon ... (Mass General Brigham)

A new Mass Eye and Ear-led study is the first to discover that people prescribed semaglutide, sold as Ozempic and Wegovy, have a higher risk of developing a ...

Post cover
Image courtesy of "NBC News"

Ozempic may be linked to condition that causes blindness, but more ... (NBC News)

People taking Ozempic and Wegovy may be at increased risk of developing a debilitating eye condition that can cause irreversible vision loss, ...

Post cover
Image courtesy of "MedPage Today"

Semaglutide May Be Linked to Condition That Causes Blindness (MedPage Today)

Use of the GLP-1 receptor agonist semaglutide (Ozempic, Wegovy) may be linked with an increased risk of the second most common form of optic neuropathy, a ...

Post cover
Image courtesy of "Drug Discovery & Development"

Study links Wegovy to increased NAION incidence in diabetes patients (Drug Discovery & Development)

An original investigation published in JAMA Ophthalmology indicated that the megablockbuster metabolic medication Wegovy (semaglutide) may increase the risk ...

Post cover
Image courtesy of "The Guardian"

Weight-loss jabs may be linked to condition that can cause ... (The Guardian)

People with diabetes on semaglutide, found in Wegovy and Ozempic, four times more likely to be diagnosed with disease of optic nerve.

Post cover
Image courtesy of "Reuters"

Wegovy, Ozempic linked with sight-threatening eye disorder in study (Reuters)

Patients using Novo Nordisk's wildly popular weigh-loss drug Wegovy and its similar medicines for type 2 diabetes may be at increased risk for a ...

Post cover
Image courtesy of "The Hill"

Ozempic, Wegovy may be linked to risk of rare form of blindness: Study (The Hill)

Those who take Ozempic or Wegovy may have an increased risk of developing a rare form of blindness, though future research is needed to make a final ...

Post cover
Image courtesy of "Seattle Medium"

Popular Weight Loss And Diabetes Drugs Linked To Increased Risk ... (Seattle Medium)

Experts agree that the potential risk of NAION should not deter the use of semaglutide medications to treat diabetes or obesity. “In the ever-changing landscape ...

Post cover
Image courtesy of "Neuroscience News"

Ozempic Linked to Increased Risk of Blinding Eye Condition ... (Neuroscience News)

A new study reveals that patients prescribed semaglutide (Ozempic or Wegovy) for diabetes or weight loss have a higher risk of developing NAION, ...

Explore the last week